James Izer, MD
Ophthalmology · Montgomery, ALNPI 1861400418
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 177 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Kala Pharmaceuticals, Inc. at 41.8% of the total. Reporting peaked in 2020 at $2,268 and has fallen 74.2% since, to $584 in 2025.
Across 177 payments — averaging $34.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kala Pharmaceuticals, Inc.$3K
- AbbVie$2K
- Bausch & Lomb Americas Inc.$374
- Sun Pharmaceutical Industries Inc.$330
- Bausch & Lomb, A Division Of Bausch Health US, LLC$326
- Alcon$281
- plus $718 from 15 others
What the payments were for
- Food & beverage$6,077100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kala Pharmaceuticals, Inc. | 16 | $2,543 |
| AbbVie(2 entities) | 66 | $1,506 |
| Bausch & Lomb Americas Inc. | 15 | $374 |
| Sun Pharmaceutical Industries Inc. | 19 | $330 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $326 |
| Alcon | 14 | $281 |
| Novartis | 12 | $191 |
| Oyster Point Pharma, Inc. | 4 | $82 |
| Harrow Eye, LLC | 2 | $62 |
| Omeros Corporation | 1 | $57 |
| Aerie Pharmaceuticals, Inc. | 3 | $52 |
| Rxsight Inc | 2 | $43 |
| Akorn, Inc. | 2 | $41 |
| Thea Pharma Inc. | 2 | $39 |
| Dompe US, Inc. | 1 | $27 |
| Sight Sciences, Inc. | 1 | $25 |
| Akorn Operating Company LLC | 1 | $25 |
| Merz Pharmaceuticals, LLC | 1 | $19 |
| Alcon Research LLC | 1 | $19 |
| Glaukos Corporation | 1 | $18 |
| Johnson & Johnson Vision Care, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,077 in reported general payments places this provider in the 85th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 425 | $229,296 |
| RestasisCyclosporine | 72 | $66,511 |
| XiidraLifitegrast | 71 | $55,983 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 127 | $28,317 |
| Cyclosporine | 49 | $27,307 |
| Prednisolone Acetate | 474 | $26,467 |
| Travoprost | 135 | $24,174 |
| TyrvayaVarenicline Tartrate | 33 | $22,729 |
| Latanoprost | 850 | $18,401 |
| CombiganBrimonidine Tartrate/Timolol | 41 | $17,371 |
| VyzultaLatanoprostene Bunod | 42 | $16,303 |
| Brinzolamide | 57 | $12,403 |
| Alphagan PBrimonidine Tartrate | 24 | $11,515 |
| Ketorolac Tromethamine | 297 | $10,686 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 50 | $10,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,506 | $324,694562 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $374 | $72,286113 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $82 | $22,72933 claims |
| AlconSimbrinza | $281 | $10,16750 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $52 | $8,85712 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $330 | $8,25913 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $326 | $4,60627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 197 ophthalmology providers in Alabama.
Other ophthalmology in Montgomery
- In ShinMontgomery$12K
- Stephen OwensMontgomery$10K
- Katherine DonnithorneMontgomery$7K
- John SwanMontgomery$6K
- Elizabeth MurphyMontgomery$4K
- Bret FisherHomewood$545K
- Caroline WatsonHuntsville$292K
- Ronald GrossFairhope$143K
- Kristin BainsBirmingham$40K
- Sebastian HeersinkDothan$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.